NIH State-of-the-Science Conference: Preventing Alzheimer's Disease and Cognitive Decline; Notice, 3243-3244 [2010-858]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 12 / Wednesday, January 20, 2010 / Notices
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/bsa.htm, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: January 14, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–992 Filed 1–19–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
pwalker on DSK8KYBLC1PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Board of
Scientific Advisors.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Cancer
Institute Board of Scientific Advisors.
Date: March 8–9, 2010.
Time: March 8, 2010, 8 a.m. to 6 p.m.
Agenda: Director’s Report: Ongoing and
New Business; Reports of Program Group(s);
and Budget Presentations; Reports of Special
Initiatives; RFA and RFP Concept Reviews;
and Scientific Presentations.
Place: National Institutes of Health,
Building 31, 31 Center Drive, 6th Floor, Conf.
Room 10, Bethesda, MD 20892.
Time: March 9, 2010, 8:30 a.m. to 12 p.m.
Agenda: Reports of Special Initiatives; RFA
and RFP Concept Reviews; and Scientific
Presentations.
Place: National Institutes of Health,
Building 31, 31 Center Drive, 6th Floor, Conf.
Room 10, Bethesda, MD 20892.
Contact Person: Paulette S. Gray, PhD,
Executive Secretary, Director, Division of
Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Rm. 8001,
Bethesda, MD 20892, 301–496–5147,
grayp@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
VerDate Nov<24>2008
16:06 Jan 19, 2010
Jkt 220001
Dated: January 13, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–993 Filed 1–19–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
NIH State-of-the-Science Conference:
Preventing Alzheimer’s Disease and
Cognitive Decline; Notice
Notice is hereby given by the National
Institutes of Health (NIH) of the ‘‘NIH
State-of-the-Science Conference:
Preventing Alzheimer’s Disease and
Cognitive Decline’’ to be held April 26–
28, 2010, in the NIH Natcher Conference
Center, 45 Center Drive, Bethesda,
Maryland 20892. The conference will
begin at 8:30 a.m. on April 26 and 27
and at 9 a.m. on April 28, and it will
be open to the public.
For many older adults, cognitive
health and performance remain stable
over the course of their lifetime, with
only a gradual and slight decline in
short-term memory and reaction times.
But for others, this normal, age-related
decline in cognitive function progresses
into a more serious state of cognitive
impairment or into various forms of
dementia, including Alzheimer’s
disease. Such loss of cognitive
function—the ability to think, learn,
remember, and reason—substantially
interferes with everyday function. As
researchers continue to explore changes
in the brain that take place possibly
decades before cognitive decline and
dementia symptoms appear, they also
hope to discover more about the
relationship between normal age-related
cognitive decline and the development
of cognitive impairment or Alzheimer’s
disease.
Alzheimer’s disease was first
described in 1906, when German
psychiatrist and neuropathologist Alois
Alzheimer observed the hallmarks of the
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
3243
disease in the brain of a female patient
who had experienced memory loss,
language problems, and unpredictable
behavior: abnormal clumps of protein
(now called beta-amyloid plaques) and
tangled bundles of protein fibers (now
called neurofibrillary tangles). Today,
an estimated 2.5 to 4.5 million
Americans are living with Alzheimer’s,
the most common form of dementia, and
those numbers are expected to grow
with the aging of the baby boomer
population. Age is the strongest known
risk factor for Alzheimer’s, with most
people diagnosed with the late-onset
form of the disease over age 60. An
early-onset, familial form also occurs,
but is very rare. The time from diagnosis
to death with Alzheimer’s ranges from
as little as 3 years to 10 or more,
depending on the person’s age, sex, and
the presence of other health problems.
In addition to investigating the causes
and potential treatments for Alzheimer’s
and other dementias, researchers are
focused on finding ways to prevent
cognitive decline. Many preventive
measures for cognitive decline and for
preventing Alzheimer’s—mental
stimulation, exercise, and a variety of
dietary supplements—have been
suggested, but their value in delaying
the onset and/or reducing the severity of
decline or disease is unclear. Questions
also remain as to how the presence of
certain conditions, such as high
cholesterol, high blood pressure, and
diabetes, influence an individual’s risk
of cognitive decline and Alzheimer’s
disease.
To examine these important questions
about Alzheimer’s and cognitive decline
in older people, the National Institute
on Aging and the Office of Medical
Applications of Research of the NIH will
convene a State-of-the-Science
Conference from April 26 to 28, 2010, to
assess the available scientific evidence
related to the following questions:
• What factors are associated with the
reduction of risk of Alzheimer’s disease?
• What factors are associated with the
reduction of risk of cognitive decline in
older adults?
• What are the relationships between
the factors that affect Alzheimer’s
disease and the factors that affect
cognitive decline?
• What are the therapeutic and
adverse effects of interventions to delay
the onset of Alzheimer’s disease?
• What are the therapeutic and
adverse effects of interventions to
improve or maintain cognitive ability or
preserve cognitive function? Are there
different outcomes in identifiable
subgroups?
• If recommendations for
interventions cannot be made currently,
E:\FR\FM\20JAN1.SGM
20JAN1
3244
Federal Register / Vol. 75, No. 12 / Wednesday, January 20, 2010 / Notices
what studies need to be done that could
provide the quality and strength of
evidence necessary to make such
recommendations to individuals?
An impartial, independent panel will
be charged with reviewing the available
published literature in advance of the
conference, including a systematic
literature review commissioned through
the Agency for Healthcare Research and
Quality. The first day and a half of the
conference will consist of presentations
by expert researchers and practitioners
and open public discussions. On
Wednesday, April 28, the panel will
present a statement of its collective
assessment of the evidence to answer
each of the questions above. The panel
will also hold a press telebriefing to
address questions from the media. The
draft statement will be published online
later that day, and the final version will
be released approximately six weeks
later. The primary sponsors of this
meeting are the NIH National Institute
on Aging and the NIH Office of Medical
Applications of Research.
Advance information about the
conference and conference registration
materials may be obtained from the NIH
Consensus Development Program
Information Center by calling 888–644–
2667 or by sending e-mail to
consensus@mail.nih.gov. The
Information Center’s mailing address is
P.O. Box 2577, Kensington, Maryland
20891. Registration information is also
available on the NIH Consensus
Development Program Web site at
https://consensus.nih.gov.
Please Note: The NIH has instituted
security measures to ensure the safety of NIH
employees, guests, and property. All visitors
must be prepared to show a photo ID upon
request. Visitors may be required to pass
through a metal detector and have bags,
backpacks, or purses inspected or x-rayed as
they enter NIH buildings. For more
information about the security measures at
NIH, please visit the Web site at https://
www.nih.gov/about/visitorsecurity.htm.
Dated: January 11, 2010.
Raynard S. Kington,
Deputy Director, National Institutes of Health.
[FR Doc. 2010–858 Filed 1–19–10; 8:45 am]
BILLING CODE 4140–01–P
pwalker on DSK8KYBLC1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Monoclonal Antibodies
Against Smallpox/Orthopoxviruses
AGENCY: National Institutes of Health,
Public Health Service, DHHS.
VerDate Nov<24>2008
16:06 Jan 19, 2010
Jkt 220001
ACTION:
Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of a an
exclusive license to practice the
following invention as embodied in the
following patent applications: E–145–
2004/0,1,2,3,4, Purcell et al.,
‘‘Monoclonal Antibodies Against
Orthopoxviruses’’, United States Patent
Application 12/142,594, filed June 19,
2008 to BioFactura, Inc., having a place
of business in Rockville, Maryland. The
patent rights in this invention have been
assigned to the United States of
America.
DATES: Only written comments and/or
application for a license which are
received by the NIH Office of
Technology Transfer on or before
February 19, 2010 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Peter Soukas, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; E-mail:
ps193c@nih.gov; Telephone: (301) 435–
4646; Facsimile: (301) 402–0220.
SUPPLEMENTARY INFORMATION: Concerns
that variola (smallpox) virus might be
used as a biological weapon have led to
the recommendation of widespread
vaccination with vaccinia virus. While
vaccination is generally safe and
effective for prevention of smallpox, it
is well documented that various adverse
reactions in individuals have been
caused by vaccination with existing
licensed vaccines. Vaccinia immune
globulin (VIG) prepared from vaccinated
humans has historically been used to
treat adverse reactions arising from
vaccinia immunization. However, VIG
lots may have different potencies and
carry the potential to transmit other
viral agents.
Chimpanzee Fabs against the B5 and
A33 outer extracellular membrane
proteins of vaccinia virus were isolated
and converted into complete mAbs with
human gamma1 heavy chain constant
regions. The two mAbs displayed high
binding affinities to B5 and A33. The
mAbs inhibited the spread of vaccinia
virus as well as variola virus (the
causative agent of smallpox) in vitro,
protected mice from subsequent
intranasal challenge with virulent
vaccinia virus, protected mice when
administered two (2) days after
challenge, and provided significantly
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
greater protection than that afforded by
VIG.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within thirty (30) days from the date of
this published Notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
The field of use may be limited to
monoclonal antibodies against
orthopoxviruses (smallpox) for use in
humans.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: January 12, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–977 Filed 1–19–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Accreditation and Approval of Saybolt
LP, as a Commercial Gauger and
Laboratory
AGENCY: U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of accreditation and
approval of Saybolt LP, as a commercial
gauger and laboratory.
SUMMARY: Notice is hereby given that,
pursuant to 19 CFR 151.12 and 19 CFR
151.13, Saybolt LP, 21730 S.
Wilmington Ave., Suite 201, Carson, CA
90810, has been approved to gauge and
accredited to test petroleum and
petroleum products in accordance with
the provisions of 19 CFR 151.12 and 19
CFR 151.13. Anyone wishing to employ
this entity to conduct laboratory
analyses and gauger services should
request and receive written assurances
from the entity that it is accredited or
approved by the U.S. Customs and
Border Protection to conduct the
specific test or gauger service requested.
E:\FR\FM\20JAN1.SGM
20JAN1
]]>Agencies
[Federal Register Volume 75, Number 12 (Wednesday, January 20, 2010)]
[Notices]
[Pages 3243-3244]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-858]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
NIH State-of-the-Science Conference: Preventing Alzheimer's
Disease and Cognitive Decline; Notice
Notice is hereby given by the National Institutes of Health (NIH)
of the ``NIH State-of-the-Science Conference: Preventing Alzheimer's
Disease and Cognitive Decline'' to be held April 26-28, 2010, in the
NIH Natcher Conference Center, 45 Center Drive, Bethesda, Maryland
20892. The conference will begin at 8:30 a.m. on April 26 and 27 and at
9 a.m. on April 28, and it will be open to the public.
For many older adults, cognitive health and performance remain
stable over the course of their lifetime, with only a gradual and
slight decline in short-term memory and reaction times. But for others,
this normal, age-related decline in cognitive function progresses into
a more serious state of cognitive impairment or into various forms of
dementia, including Alzheimer's disease. Such loss of cognitive
function--the ability to think, learn, remember, and reason--
substantially interferes with everyday function. As researchers
continue to explore changes in the brain that take place possibly
decades before cognitive decline and dementia symptoms appear, they
also hope to discover more about the relationship between normal age-
related cognitive decline and the development of cognitive impairment
or Alzheimer's disease.
Alzheimer's disease was first described in 1906, when German
psychiatrist and neuropathologist Alois Alzheimer observed the
hallmarks of the disease in the brain of a female patient who had
experienced memory loss, language problems, and unpredictable behavior:
abnormal clumps of protein (now called beta-amyloid plaques) and
tangled bundles of protein fibers (now called neurofibrillary tangles).
Today, an estimated 2.5 to 4.5 million Americans are living with
Alzheimer's, the most common form of dementia, and those numbers are
expected to grow with the aging of the baby boomer population. Age is
the strongest known risk factor for Alzheimer's, with most people
diagnosed with the late-onset form of the disease over age 60. An
early-onset, familial form also occurs, but is very rare. The time from
diagnosis to death with Alzheimer's ranges from as little as 3 years to
10 or more, depending on the person's age, sex, and the presence of
other health problems.
In addition to investigating the causes and potential treatments
for Alzheimer's and other dementias, researchers are focused on finding
ways to prevent cognitive decline. Many preventive measures for
cognitive decline and for preventing Alzheimer's--mental stimulation,
exercise, and a variety of dietary supplements--have been suggested,
but their value in delaying the onset and/or reducing the severity of
decline or disease is unclear. Questions also remain as to how the
presence of certain conditions, such as high cholesterol, high blood
pressure, and diabetes, influence an individual's risk of cognitive
decline and Alzheimer's disease.
To examine these important questions about Alzheimer's and
cognitive decline in older people, the National Institute on Aging and
the Office of Medical Applications of Research of the NIH will convene
a State-of-the-Science Conference from April 26 to 28, 2010, to assess
the available scientific evidence related to the following questions:
What factors are associated with the reduction of risk of
Alzheimer's disease?
What factors are associated with the reduction of risk of
cognitive decline in older adults?
What are the relationships between the factors that affect
Alzheimer's disease and the factors that affect cognitive decline?
What are the therapeutic and adverse effects of
interventions to delay the onset of Alzheimer's disease?
What are the therapeutic and adverse effects of
interventions to improve or maintain cognitive ability or preserve
cognitive function? Are there different outcomes in identifiable
subgroups?
If recommendations for interventions cannot be made
currently,
[[Page 3244]]
what studies need to be done that could provide the quality and
strength of evidence necessary to make such recommendations to
individuals?
An impartial, independent panel will be charged with reviewing the
available published literature in advance of the conference, including
a systematic literature review commissioned through the Agency for
Healthcare Research and Quality. The first day and a half of the
conference will consist of presentations by expert researchers and
practitioners and open public discussions. On Wednesday, April 28, the
panel will present a statement of its collective assessment of the
evidence to answer each of the questions above. The panel will also
hold a press telebriefing to address questions from the media. The
draft statement will be published online later that day, and the final
version will be released approximately six weeks later. The primary
sponsors of this meeting are the NIH National Institute on Aging and
the NIH Office of Medical Applications of Research.
Advance information about the conference and conference
registration materials may be obtained from the NIH Consensus
Development Program Information Center by calling 888-644-2667 or by
sending e-mail to consensus@mail.nih.gov. The Information Center's
mailing address is P.O. Box 2577, Kensington, Maryland 20891.
Registration information is also available on the NIH Consensus
Development Program Web site at https://consensus.nih.gov.
Please Note: The NIH has instituted security measures to ensure
the safety of NIH employees, guests, and property. All visitors must
be prepared to show a photo ID upon request. Visitors may be
required to pass through a metal detector and have bags, backpacks,
or purses inspected or x-rayed as they enter NIH buildings. For more
information about the security measures at NIH, please visit the Web
site at https://www.nih.gov/about/visitorsecurity.htm.
Dated: January 11, 2010.
Raynard S. Kington,
Deputy Director, National Institutes of Health.
[FR Doc. 2010-858 Filed 1-19-10; 8:45 am]
BILLING CODE 4140-01-P
